{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:33:02Z","timestamp":1792758782772,"version":"4.5.0"},"reference-count":281,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T00:00:00Z","timestamp":1697587200000},"content-version":"unspecified","delay-in-days":17,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2023,7,16]]},"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:p>\n                    Since the first approval for immune checkpoint inhibitors (ICIs) for the treatment of cutaneous melanoma more than a decade ago, immunotherapy has completely transformed the treatment landscape of this chemotherapy-resistant disease. Combination regimens including ICIs directed against programmed cell death protein 1 (PD-1) with anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) agents or, more recently, anti-lymphocyte-activation gene 3 (LAG-3) agents, have gained regulatory approvals for the treatment of metastatic cutaneous melanoma, with long-term follow-up data suggesting the possibility of cure for some patients with advanced disease. In the resectable setting, adjuvant ICIs prolong recurrence-free survival and several are FDA-approved. Although not yet approved, neoadjuvant ICIs have also shown to improve event-free survival and remains an ongoing area of investigation. Other immunotherapy strategies, such as oncolytic virotherapy for injectable cutaneous melanoma, bispecific T-cell engager therapy for HLA-A*02:01 genotype-positive uveal melanoma, and lifileucel, an autologous tumor-infiltrating lymphocyte therapy, for unresectable or metastatic melanoma are also available to patients. Despite the remarkable efficacy of these regimens for many patients with cutaneous melanoma, traditional immunotherapy biomarkers (ie, programmed death-ligand 1 expression, tumor mutational burden, T-cell infiltrate and\/or microsatellite stability) have failed to reliably predict response. Furthermore, ICIs are associated with unique toxicity profiles, particularly for the highly active combination of anti-PD-1 plus anti-CTLA-4 agents. The Society for Immunotherapy of Cancer (SITC) convened a panel of experts to develop this clinical practice guideline on immunotherapy for the treatment of melanoma, including rare subtypes of the disease (eg, uveal, mucosal), with the goal of improving patient care by providing guidance to the oncology community. Drawing from published data and clinical experience, the Expert Panel developed evidence- and consensus-based recommendations for healthcare professionals using immunotherapy to treat melanoma, with topics including therapy selection in the advanced and perioperative settings, intratumoral immunotherapy, when to use immunotherapy for patients with\n                    <jats:italic>BRAF<\/jats:italic>\n                    V600-mutated disease, management of patients with brain metastases, evaluation of treatment response, special patient populations, patient education, quality of life, and survivorship, among others.\n                  <\/jats:p>","DOI":"10.1136\/jitc-2023-006947","type":"journal-article","created":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T13:11:53Z","timestamp":1697634713000},"page":"e006947","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":68,"title":["Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct04169321","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04099251","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00636168","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02388906","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02362594","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03553836","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04309409","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05270044","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03757689","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03897881","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04207086","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04949113","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03554083","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00094653","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01704287","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01927419","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01721772","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01866319","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01844505","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02908672","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03470922","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02224781","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04511013","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02939300","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03091478","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03719768","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03025256","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04562129","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04462406","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04462406","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03070392","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04622566","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02360579","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05640193","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7088-0742","authenticated-orcid":false,"given":"Anna C","family":"Pavlick","sequence":"first","affiliation":[{"name":"Weill Cornell Medicine, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte E","family":"Ariyan","sequence":"additional","affiliation":[{"name":"Department of Surgery Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth I","family":"Buchbinder","sequence":"additional","affiliation":[{"name":"Melanoma Disease Center, Dana Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7846-8055","authenticated-orcid":false,"given":"Diwakar","family":"Davar","sequence":"additional","affiliation":[{"name":"Hillman Cancer Center, University of Pittsburg Medical Center, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5401-8498","authenticated-orcid":false,"given":"Geoffrey T","family":"Gibney","sequence":"additional","affiliation":[{"name":"Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, Washington, District of Columbia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omid","family":"Hamid","sequence":"additional","affiliation":[{"name":"The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina J","family":"Hieken","sequence":"additional","affiliation":[{"name":"Department of Surgery and Comprehensive Cancer Center, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2379-6702","authenticated-orcid":false,"given":"Benjamin","family":"Izar","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology\/Oncology, Columbia University Medical Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas B","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2191-4085","authenticated-orcid":false,"given":"Rajan P","family":"Kulkarni","sequence":"additional","affiliation":[{"name":"Departments of Dermatology, Oncological Sciences, Biomedical Engineering, and Center for Cancer Early Detection Advanced Research, Knight Cancer Institute, OHSU, Portland, Oregon, USA"},{"name":"Operative Care Division, VA Portland Health Care System (VAPORHCS), Portland, Oregon, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1182-4908","authenticated-orcid":false,"given":"Jason J","family":"Luke","sequence":"additional","affiliation":[{"name":"Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara C","family":"Mitchell","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8289-8015","authenticated-orcid":false,"given":"Meghan J","family":"Mooradian","sequence":"additional","affiliation":[{"name":"Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista M","family":"Rubin","sequence":"additional","affiliation":[{"name":"Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April KS","family":"Salama","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Medical Oncology, Duke University, Durham, Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Shirai","sequence":"additional","affiliation":[{"name":"Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janis M","family":"Taube","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1942-851X","authenticated-orcid":false,"given":"Hussein A","family":"Tawbi","sequence":"additional","affiliation":[{"name":"Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J Keith","family":"Tolley","sequence":"additional","affiliation":[{"name":"Patient Advocate, Melanoma Research Alliance, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caressa","family":"Valdueza","sequence":"additional","affiliation":[{"name":"Cutaneous Oncology Program, Weill Cornell Medicine, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah A","family":"Weiss","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7526-1262","authenticated-orcid":false,"given":"Michael K","family":"Wong","sequence":"additional","affiliation":[{"name":"Patient Advocate, Melanoma Research Alliance, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5344-6645","authenticated-orcid":false,"given":"Ryan J","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,10,18]]},"reference":[{"key":"2026052004550431000_11.10.e006947.1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2010.28.15_suppl.8511","article-title":"Final results of E2603: A double-blind, randomized phase III trial comparing carboplatin (C)\/Paclitaxel (P) with or without sorafenib (S) in metastatic Melanoma","volume":"28","author":"Flaherty","year":"2010","journal-title":"JCO"},{"key":"2026052004550431000_11.10.e006947.2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19840315)53:6<1299::AID-CNCR2820530613>3.0.CO;2-4"},{"key":"2026052004550431000_11.10.e006947.3","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/SLA.0b013e31828421e1","article-title":"The importance of adequate primary tumor Excision margins and sentinel node biopsy in achieving optimal Locoregional control for patients with thick primary Melanomas","volume":"258","author":"Pasquali","year":"2013","journal-title":"Ann Surg"},{"key":"2026052004550431000_11.10.e006947.4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.7.2105"},{"key":"2026052004550431000_11.10.e006947.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"key":"2026052004550431000_11.10.e006947.6","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.9506","article-title":"Checkmate 067: 6.5-year outcomes in patients (Pts) with advanced Melanoma","volume":"39","author":"Wolchok","year":"2021","journal-title":"JCO"},{"key":"2026052004550431000_11.10.e006947.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109970"},{"key":"2026052004550431000_11.10.e006947.8","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000948","article-title":"Evolving impact of long-term survival results on metastatic Melanoma treatment","volume":"8","author":"Michielin","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026052004550431000_11.10.e006947.9","unstructured":"Food and Drug Administration (FDA), Iovance . Lifileucel (AMTAGVI) prescribing information. 2024. Available: https:\/\/www.fda.gov\/vaccines-blood-biologics\/approved-blood-products\/amtagvi"},{"key":"2026052004550431000_11.10.e006947.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.02.017"},{"key":"2026052004550431000_11.10.e006947.11","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1016\/j.ophtha.2012.02.017","article-title":"Collaborative ocular oncology group report number 1: prospective validation of a multi-gene Prognostic assay in Uveal Melanoma","volume":"119","author":"Onken","year":"2012","journal-title":"Ophthalmology"},{"key":"2026052004550431000_11.10.e006947.12","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2016.67.2477"},{"key":"2026052004550431000_11.10.e006947.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910836"},{"key":"2026052004550431000_11.10.e006947.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910836"},{"key":"2026052004550431000_11.10.e006947.15","doi-asserted-by":"crossref","unstructured":"Long GV , Schadendorf D , Vecchio MD , et al . Abstract Ct004: adjuvant therapy with Nivolumab (NIVO) combined with Ipilimumab (IPI) vs NIVO alone in patients (Pts) with Resected stage IIIB-D\/IV Melanoma (Checkmate 915). Cancer Res 2021;81. doi:10.1158\/1538-7445.AM2021-CT004","DOI":"10.1158\/1538-7445.AM2021-CT004"},{"key":"2026052004550431000_11.10.e006947.16","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-020-01187-x"},{"key":"2026052004550431000_11.10.e006947.17","doi-asserted-by":"publisher","DOI":"10.1038\/nature12477"},{"key":"2026052004550431000_11.10.e006947.18","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar3593"},{"key":"2026052004550431000_11.10.e006947.19","doi-asserted-by":"crossref","DOI":"10.1126\/science.aar3593","article-title":"Pan-tumor Genomic biomarkers for PD-1 Checkpoint blockade\u2013based Immunotherapy","volume":"362","author":"Cristescu","year":"2018","journal-title":"Science"},{"key":"2026052004550431000_11.10.e006947.20","article-title":"Positive association between location of Melanoma, ultraviolet signature, tumor mutational burden, and response to anti-PD-1 therapy","volume":"5","author":"Dousset","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"2026052004550431000_11.10.e006947.21","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-20-0983"},{"key":"2026052004550431000_11.10.e006947.22","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1158\/2326-6066.CIR-20-0983","article-title":"TMB and inflammatory gene expression associated with clinical outcomes following Immunotherapy in advanced Melanoma","volume":"9","author":"Hodi","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"2026052004550431000_11.10.e006947.23","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.666624","article-title":"Are molecular alterations linked to genetic instability worth to be included as biomarkers for directing or excluding Melanoma patients to Immunotherapy","volume":"11","author":"Palmieri","year":"2021","journal-title":"Front Oncol"},{"key":"2026052004550431000_11.10.e006947.24","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/00008390-200304000-00009","article-title":"Assessment of genetic instability in Melanocytic skin lesions through Microsatellite analysis of benign Naevi, Dysplastic Naevi, and primary Melanomas and their metastases","volume":"13","author":"Palmieri","year":"2003","journal-title":"Melanoma Res"},{"key":"2026052004550431000_11.10.e006947.25","article-title":"Frequency of mismatch repair gene mutations in Uveal Melanoma","volume":"60","author":"Toomey","year":"2019","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2026052004550431000_11.10.e006947.26","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1097\/IAE.0000000000002732","article-title":"PREVALENCE of mismatch repair gene mutations in uveal melanoma","volume":"40","author":"Toomey","year":"2020","journal-title":"Retina"},{"key":"2026052004550431000_11.10.e006947.27","doi-asserted-by":"publisher","DOI":"10.1309\/AJCPCX2D9YULBBLG"},{"key":"2026052004550431000_11.10.e006947.28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1414428"},{"key":"2026052004550431000_11.10.e006947.29","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2018-105610"},{"key":"2026052004550431000_11.10.e006947.30","doi-asserted-by":"publisher","DOI":"10.1172\/JCI91190"},{"key":"2026052004550431000_11.10.e006947.31","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0367-1"},{"key":"2026052004550431000_11.10.e006947.32","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-018-0367-1","article-title":"Pan-cancer adaptive immune resistance as defined by the tumor inflammation signature (TIS): results from the cancer genome Atlas (TCGA)","volume":"6","author":"Danaher","year":"2018","journal-title":"J Immunother Cancer"},{"key":"2026052004550431000_11.10.e006947.33","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1158\/1078-0432.CCR-15-0321","article-title":"Correlation of BRAF Mutation status in circulating-free DNA and tumor and association with clinical outcome across four Brafi and Meki clinical trials","volume":"22","author":"Santiago-Walker","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2026052004550431000_11.10.e006947.34","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/annonc\/mdx717","article-title":"Circulating tumor DNA predicts survival in patients with Resected high-risk stage II\/III Melanoma","volume":"29","author":"Lee","year":"2018","journal-title":"Ann Oncol"},{"key":"2026052004550431000_11.10.e006947.35","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/annonc\/mdx026","article-title":"Circulating tumour DNA predicts response to anti-Pd1 antibodies in metastatic Melanoma","volume":"28","author":"Lee","year":"2017","journal-title":"Ann Oncol"},{"key":"2026052004550431000_11.10.e006947.36","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-3346"},{"key":"2026052004550431000_11.10.e006947.37","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000291"},{"key":"2026052004550431000_11.10.e006947.38","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000291","article-title":"Granzyme B PET imaging of immune-mediated tumor killing as a tool for understanding Immunotherapy response","volume":"8","author":"LaSalle","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026052004550431000_11.10.e006947.39","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01406-6"},{"key":"2026052004550431000_11.10.e006947.40","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan4236"},{"key":"2026052004550431000_11.10.e006947.41","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut Microbiome modulates response to anti-PD-1 Immunotherapy in Melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"key":"2026052004550431000_11.10.e006947.42","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.9503"},{"key":"2026052004550431000_11.10.e006947.43","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.9503","article-title":"Relatlimab (RELA) plus Nivolumab (NIVO) versus NIVO in first-line advanced Melanoma: primary phase III results from RELATIVITY-047 (Ca224-047)","volume":"39","author":"Lipson","year":"2021","journal-title":"JCO"},{"key":"2026052004550431000_11.10.e006947.44","doi-asserted-by":"crossref","DOI":"10.1186\/1479-5876-11-75","article-title":"Gene expression profiling of whole blood in Ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events","volume":"11","author":"Shahabi","year":"2013","journal-title":"J Transl Med"},{"key":"2026052004550431000_11.10.e006947.45","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003625","article-title":"Germline biomarkers predict toxicity to anti-Pd1\/Pdl1 Checkpoint therapy","volume":"10","author":"Weidhaas","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026052004550431000_11.10.e006947.46","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01623-z"},{"key":"2026052004550431000_11.10.e006947.47","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01623-z"},{"key":"2026052004550431000_11.10.e006947.48","doi-asserted-by":"crossref","unstructured":"Zhang D , Shah N , Cook M , et al . n.d. Association between body mass index and immune-related adverse events (irAEs) among advanced-stage cancer patients receiving immune Checkpoint inhibitors: A pan-cancer analysis. Cancers;13:6109. doi:10.3390\/cancers13236109","DOI":"10.3390\/cancers13236109"},{"key":"2026052004550431000_11.10.e006947.49","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10391","article-title":"Intestinal Microbiome analyses identify Melanoma patients at risk for Checkpoint-blockade-induced colitis","volume":"7","author":"Dubin","year":"2016","journal-title":"Nat Commun"},{"key":"2026052004550431000_11.10.e006947.50","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/s41591-022-01698-2","article-title":"Intestinal Microbiota signatures of clinical response and immune-related adverse events in Melanoma patients treated with anti-PD-1","volume":"28","author":"McCulloch","year":"2022","journal-title":"Nat Med"},{"key":"2026052004550431000_11.10.e006947.51","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21409"},{"key":"2026052004550431000_11.10.e006947.52","first-page":"472","article-title":"Melanoma staging: evidence-based changes in the American joint committee on cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"2026052004550431000_11.10.e006947.53","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1200\/JCO.2016.70.2951","article-title":"Phase III randomized study of 4 weeks of high-dose interferon-\u0391-2B in stage T2Bno, T3A-bNO, T4A-bNO, and T1-4N1A-2A (microscopic) Melanoma: A trial of the Eastern cooperative oncology group-American college of Radiology imaging network cancer research group (E1697)","volume":"35","author":"Agarwala","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026052004550431000_11.10.e006947.54","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1245\/s10434-016-5642-0","article-title":"Patterns and timing of initial relapse in pathologic stage II Melanoma patients","volume":"24","author":"Lee","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"2026052004550431000_11.10.e006947.55","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1200\/JCO.22.00202","article-title":"Prognosis of patients with primary Melanoma stage I and II according to American joint committee on cancer version 8 validated in two independent cohorts: implications for adjuvant treatment","volume":"40","author":"Garbe","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026052004550431000_11.10.e006947.56","doi-asserted-by":"crossref","first-page":"S1314","DOI":"10.1016\/j.annonc.2021.08.2116","article-title":"Pembrolizumab versus placebo after complete resection of high-risk stage II Melanoma: efficacy and safety results from the KEYNOTE-716 double-blind phase III trial","volume":"32","author":"Luke","year":"2021","journal-title":"Annals of Oncology"},{"key":"2026052004550431000_11.10.e006947.57","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00559-9"},{"key":"2026052004550431000_11.10.e006947.58","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/S1470-2045(22)00559-9","article-title":"Pembrolizumab versus placebo as adjuvant therapy in Resected stage IIB or IIC Melanoma (KEYNOTE-716): distant metastasis-free survival results of a Multicentre, double-blind, randomised, phase 3 trial","volume":"23","author":"Long","year":"2022","journal-title":"Lancet Oncol"},{"key":"2026052004550431000_11.10.e006947.59","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1038\/s41591-023-02583-2","article-title":"Adjuvant nivolumab in resected stage IIB\/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial","volume":"29","author":"Kirkwood","year":"2023","journal-title":"Nat Med"},{"key":"2026052004550431000_11.10.e006947.60","unstructured":"Food and Drug Administration (FDA), BMS . Nivolumab (OPDIVO) prescribing information. 2024. Available: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=125554"},{"key":"2026052004550431000_11.10.e006947.61","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.4799"},{"key":"2026052004550431000_11.10.e006947.62","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70122-1"},{"key":"2026052004550431000_11.10.e006947.63","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1802357"},{"key":"2026052004550431000_11.10.e006947.64","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC Melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"JCO"},{"key":"2026052004550431000_11.10.e006947.65","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant Ipilimumab versus placebo after complete resection of high-risk stage III Melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol"},{"key":"2026052004550431000_11.10.e006947.66","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1802357"},{"key":"2026052004550431000_11.10.e006947.67","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)00141-8"},{"key":"2026052004550431000_11.10.e006947.68","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1200\/JCO.19.03034","article-title":"Prognosis of patients with stage III Melanoma according to American joint committee on cancer version 8: A reassessment on the basis of 3 independent stage III Melanoma cohorts","volume":"38","author":"Garbe","year":"2020","journal-title":"JCO"},{"key":"2026052004550431000_11.10.e006947.69","unstructured":"NCCN . Melanoma: cutaneous 2023. 2023. Available: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cutaneous_melanoma.pdf"},{"key":"2026052004550431000_11.10.e006947.70","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1470-2045(16)00141-8","article-title":"Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive Melanoma (Decog-SLT): a Multicentre, randomised, phase 3 trial","volume":"17","author":"Leiter","year":"2016","journal-title":"Lancet Oncol"},{"key":"2026052004550431000_11.10.e006947.71","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61033-8"},{"key":"2026052004550431000_11.10.e006947.72","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.1996.14.1.7","article-title":"Interferon Alfa-2B adjuvant therapy of high-risk Resected cutaneous Melanoma: the Eastern cooperative oncology group trial EST 1684","volume":"14","author":"Kirkwood","year":"1996","journal-title":"J Clin Oncol"},{"key":"2026052004550431000_11.10.e006947.73","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.01381"},{"key":"2026052004550431000_11.10.e006947.74","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709030"},{"key":"2026052004550431000_11.10.e006947.75","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.2512","article-title":"Ipilimumab versus placebo after complete resection of stage III Melanoma: long-term follow-up results the EORTC 18071 double-blind phase 3 randomized trial","volume":"37","author":"Eggermont","year":"2019","journal-title":"JCO"},{"key":"2026052004550431000_11.10.e006947.76","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1200\/JCO.19.01381","article-title":"Phase III study of adjuvant Ipilimumab (3 or 10 mg\/kg) versus high-dose interferon Alfa-2B for Resected high-risk Melanoma: North American Intergroup E1609","volume":"38","author":"Tarhini","year":"2020","journal-title":"JCO"},{"key":"2026052004550431000_11.10.e006947.77","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00065-6"},{"key":"2026052004550431000_11.10.e006947.78","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/S1470-2045(20)30494-0","article-title":"Adjuvant Nivolumab versus Ipilimumab in Resected stage IIIB\u2013C and stage IV Melanoma (Checkmate 238): 4-year results from a Multicentre, double-blind, randomised, controlled, phase 3 trial","volume":"21","author":"Ascierto","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026052004550431000_11.10.e006947.79","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.9502","article-title":"Adjuvant therapy with Nivolumab (NIVO) versus Ipilimumab (IPI) after complete resection of stage III\/IV Melanoma: updated results from a phase III trial (Checkmate 238)","volume":"36","author":"Weber","year":"2018","journal-title":"JCO"},{"key":"2026052004550431000_11.10.e006947.80","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S1470-2045(21)00065-6","article-title":"Adjuvant Pembrolizumab versus placebo in Resected stage III Melanoma (EORTC 1325-MG\/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial","volume":"22","author":"Eggermont","year":"2021","journal-title":"Lancet Oncol"},{"key":"2026052004550431000_11.10.e006947.81","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.9501","article-title":"Final analysis of overall survival (OS) and relapse-free-survival (RFS) in the intergroup S1404 phase III randomized trial comparing either high-dose interferon (HDI) or Ipilimumab to Pembrolizumab in patients with high-risk Resected Melanoma","volume":"39","author":"Grossmann","year":"2021","journal-title":"JCO"},{"key":"2026052004550431000_11.10.e006947.82","doi-asserted-by":"publisher","DOI":"10.1245\/ASO.2005.05.025"},{"key":"2026052004550431000_11.10.e006947.83","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S0140-6736(20)30417-7","article-title":"Adjuvant Nivolumab plus Ipilimumab or Nivolumab monotherapy versus placebo in patients with Resected stage IV Melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"395","author":"Zimmer","year":"2020","journal-title":"Lancet"},{"key":"2026052004550431000_11.10.e006947.84","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S0140-6736(22)01654-3","article-title":"Adjuvant Nivolumab plus Ipilimumab or Nivolumab alone versus placebo in patients with Resected stage IV Melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial","volume":"400","author":"Livingstone","year":"2022","journal-title":"Lancet"},{"key":"2026052004550431000_11.10.e006947.85","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708539"},{"key":"2026052004550431000_11.10.e006947.86","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2005493"},{"key":"2026052004550431000_11.10.e006947.87","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.9569","article-title":"Analysis of patients (Pts) with in-transit metastases treated with Nivolumab (NIVO) or Ipilimumab (IPI) in Checkmate 238","volume":"39","author":"Larkin","year":"2021","journal-title":"JCO"},{"key":"2026052004550431000_11.10.e006947.88","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant Dabrafenib plus Trametinib in stage III BRAF-Mutated Melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N Engl J Med"},{"key":"2026052004550431000_11.10.e006947.89","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2005493"},{"key":"2026052004550431000_11.10.e006947.90","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of cancer (SITC) clinical practice guideline on immune Checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026052004550431000_11.10.e006947.91","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1001\/jamaoncol.2021.0051","article-title":"Chronic immune-related adverse events following adjuvant anti-PD-1 therapy for high-risk Resected Melanoma","volume":"7","author":"Patrinely","year":"2021","journal-title":"JAMA Oncol"},{"key":"2026052004550431000_11.10.e006947.92","doi-asserted-by":"crossref","unstructured":"Adams L , Chick R , Clifton G , et al . 300 Final analysis of a prospective, randomized, double-blind, placebo-controlled phase iib trial of tumor lysate, particle-loaded, dendritic cell vaccine in stage III\/IV melanoma: 36-month analysis. 35th Anniversary Annual Meeting (SITC 2020); November 2020: doi:10.1136\/jitc-2020-SITC2020.0300","DOI":"10.1136\/jitc-2020-SITC2020.0300"},{"key":"2026052004550431000_11.10.e006947.93","unstructured":"Moderna and Merck announce mRNA-4157\/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA (Pembrolizumab), met primary efficacy Endpoint in phase 2B KEYNOTE-942 trial [press release]. December 13, 2022. 2022."},{"key":"2026052004550431000_11.10.e006947.94","doi-asserted-by":"crossref","first-page":"5241","DOI":"10.1245\/s10434-022-11622-0","article-title":"Neoadjuvant systemic therapy (NAST) in patients with Melanoma: surgical considerations by the International Neoadjuvant Melanoma consortium (INMC)","volume":"29","author":"van Akkooi","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"2026052004550431000_11.10.e006947.95","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.9502","article-title":"Neoadjuvant and adjuvant Nivolumab (Nivo) with anti-Lag3 antibody Relatlimab (Rela) for patients (Pts) with Resectable clinical stage III Melanoma","volume":"39","author":"Amaria","year":"2021","journal-title":"JCO"},{"key":"2026052004550431000_11.10.e006947.96","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41586-022-05368-8","article-title":"Neoadjuvant Relatlimab and Nivolumab in Resectable Melanoma","volume":"611","author":"Amaria","year":"2022","journal-title":"Nature"},{"key":"2026052004550431000_11.10.e006947.97","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdy424.052","article-title":"Opacin-Neo: a multicenter phase II study to identify the optimal Neo-adjuvant combination scheme of Ipilimumab (IPI) and Nivolumab (NIVO)","volume":"29","author":"Blank","year":"2018","journal-title":"Ann Oncol"},{"key":"2026052004550431000_11.10.e006947.98","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.10002","article-title":"First safety and efficacy results of PRADO: A phase II study of personalized response-driven surgery and adjuvant therapy after Neoadjuvant Ipilimumab (IPI) and Nivolumab (NIVO) in Resectable stage III Melanoma","volume":"38","author":"Blank","year":"2020","journal-title":"JCO"},{"key":"2026052004550431000_11.10.e006947.99","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.9501","article-title":"Survival data of PRADO: a phase 2 study of personalized response-driven surgery and adjuvant therapy after Neoadjuvant Ipilimumab (IPI) and Nivolumab (NIVO) in Resectable stage III Melanoma","volume":"40","author":"Blank","year":"2022","journal-title":"JCO"},{"key":"2026052004550431000_11.10.e006947.100","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211437"},{"key":"2026052004550431000_11.10.e006947.101","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30151-2"},{"key":"2026052004550431000_11.10.e006947.102","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2022.08.039","article-title":"LBA6 neoadjvuant versus adjuvant pembrolizumab for resected stage III-IV melanoma (SWOG S1801)","volume":"33","author":"Patel","year":"2022","journal-title":"Ann Oncol"},{"key":"2026052004550431000_11.10.e006947.103","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant\u2013adjuvant or adjuvant-only Pembrolizumab in advanced Melanoma","volume":"388","author":"Patel","year":"2023","journal-title":"N Engl J Med"},{"key":"2026052004550431000_11.10.e006947.104","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2018.1489246"},{"key":"2026052004550431000_11.10.e006947.105","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104621"},{"key":"2026052004550431000_11.10.e006947.106","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093"},{"key":"2026052004550431000_11.10.e006947.107","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(19)30388-2"},{"key":"2026052004550431000_11.10.e006947.108","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412082"},{"key":"2026052004550431000_11.10.e006947.109","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus Dacarbazine for previously untreated metastatic Melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"key":"2026052004550431000_11.10.e006947.110","doi-asserted-by":"publisher","DOI":"10.1038\/nature25187"},{"key":"2026052004550431000_11.10.e006947.111","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus Ipilimumab in advanced Melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, Multicentre, randomised, controlled, phase 3 study","volume":"20","author":"Robert","year":"2019","journal-title":"Lancet Oncol"},{"key":"2026052004550431000_11.10.e006947.112","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412082"},{"key":"2026052004550431000_11.10.e006947.113","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.11.009"},{"key":"2026052004550431000_11.10.e006947.114","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1821218116"},{"key":"2026052004550431000_11.10.e006947.115","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.9502","article-title":"Neoadjuvant PD-1 blockade in patients with Resectable Desmoplastic Melanoma (SWOG 1512)","volume":"40","author":"Kendra","year":"2022","journal-title":"JCO"},{"key":"2026052004550431000_11.10.e006947.116","unstructured":"Wolchok JD , Chiarion-Sileni V , Gonzalez R , et al . Overall survival with combined Nivolumab and Ipilimumab in advanced Melanoma. N Engl J Med 2017:1345\u201356."},{"key":"2026052004550431000_11.10.e006947.117","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1016\/j.cell.2017.11.009","article-title":"Combination cancer therapy can confer benefit via patient-to-patient variability without drug Additivity or synergy","volume":"171","author":"Palmer","year":"2017","journal-title":"Cell"},{"key":"2026052004550431000_11.10.e006947.118","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30126-7"},{"key":"2026052004550431000_11.10.e006947.119","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2015-2860","article-title":"Abstract 2860: improved clinical response in patients with advanced Melanoma treated with Nivolumab combined with Ipilimumab compared to Ipilimumab alone","volume":"75","author":"Hodi","year":"2015","journal-title":"Cancer Res"},{"key":"2026052004550431000_11.10.e006947.120","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030"},{"key":"2026052004550431000_11.10.e006947.121","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.9516","article-title":"Two dosing regimens of Nivolumab (NIVO) plus Ipilimumab (IPI) for advanced (Adv) Melanoma: three-year results of Checkmate 511","volume":"39","author":"Lebbe","year":"2021","journal-title":"JCO"},{"key":"2026052004550431000_11.10.e006947.122","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30934-X"},{"key":"2026052004550431000_11.10.e006947.123","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001806"},{"key":"2026052004550431000_11.10.e006947.124","doi-asserted-by":"crossref","unstructured":"Long GV , Stephen Hodi F , Lipson EJ , et al . Overall survival and response with Nivolumab and Relatlimab in advanced Melanoma. NEJM Evidence 2023;2. doi:10.1056\/EVIDoa2200239","DOI":"10.1056\/EVIDoa2200239"},{"key":"2026052004550431000_11.10.e006947.125","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.9515","article-title":"Clinical activity of Fianlimab (Regn3767), a human anti-LAG-3 Monoclonal antibody, combined with Cemiplimab (anti-PD-1) in patients (Pts) with advanced Melanoma","volume":"39","author":"Hamid","year":"2021","journal-title":"JCO"},{"key":"2026052004550431000_11.10.e006947.126","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30934-X"},{"key":"2026052004550431000_11.10.e006947.127","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001806","article-title":"KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of Pembrolizumab, Dabrafenib, and Trametinib in","volume":"8","author":"Ferrucci","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026052004550431000_11.10.e006947.128","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2020.08.2273","article-title":"Lba43 Spartalizumab plus Dabrafenib and Trametinib (Sparta-Dabtram) in patients (Pts) with previously untreated BRAF V600\u2013mutant Unresectable or metastatic Melanoma: results from the randomized part 3 of the phase III COMBI-I trial","volume":"31","author":"Nathan","year":"2020","journal-title":"Ann Oncol"},{"key":"2026052004550431000_11.10.e006947.129","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02961"},{"key":"2026052004550431000_11.10.e006947.130","doi-asserted-by":"crossref","unstructured":"Dummer R , Queirolo P , Gerard Duhard P , et al . Atezolizumab, Vemurafenib, and Cobimetinib in patients with Melanoma with CNS metastases (TRICOTEL): a Multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 2023:00334\u20130.:S1470-2045(23)00334-0. doi:10.1016\/S1470-2045(23)00334-0","DOI":"10.1016\/S1470-2045(23)00334-0"},{"key":"2026052004550431000_11.10.e006947.131","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.36_suppl.356154","article-title":"Dreamseq (Doublet, randomized evaluation in advanced Melanoma sequencing): a phase III trial\u2014Ecog-Acrin Ea6134","volume":"39","author":"Atkins","year":"2021","journal-title":"JCO"},{"key":"2026052004550431000_11.10.e006947.132","doi-asserted-by":"crossref","first-page":"S1173","DOI":"10.1016\/j.annonc.2020.08.2275","article-title":"Lba45 first report of efficacy and safety from the phase II study SECOMBIT (sequential combo Immuno and targeted therapy study)","volume":"31","author":"Ascierto","year":"2020","journal-title":"Annals of Oncology"},{"key":"2026052004550431000_11.10.e006947.133","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30429-1"},{"key":"2026052004550431000_11.10.e006947.134","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32375"},{"key":"2026052004550431000_11.10.e006947.135","doi-asserted-by":"crossref","unstructured":"Glitza IC , Heimberger AB , Sulman EP , et al . Chapter 19 - Prognostic factors for survival in Melanoma patients with brain metastases. In: Hayat MA , ed. Brain Metastases from Primary Tumors, Volume 3. San Diego: Academic Press, 2016: 267\u201397.","DOI":"10.1016\/B978-0-12-803508-5.00019-6"},{"key":"2026052004550431000_11.10.e006947.136","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1805453","article-title":"Nivolumab and Ipilimumab in Melanoma metastatic to the brain","volume":"379","author":"Tawbi","year":"2018","journal-title":"N Engl J Med"},{"key":"2026052004550431000_11.10.e006947.137","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00083-2"},{"key":"2026052004550431000_11.10.e006947.138","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1002\/cncr.32375","article-title":"The impact of targeted therapies and Immunotherapy in Melanoma brain metastases: A systematic review and meta-analysis","volume":"125","author":"Rulli","year":"2019","journal-title":"Cancer"},{"key":"2026052004550431000_11.10.e006947.139","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000398"},{"key":"2026052004550431000_11.10.e006947.140","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/nov218.07","article-title":"Imct-07Therapeutic outcomes of intrathecal Interleukin-2 in metastatic Melanoma patients with Leptomeningeal disease (Lmd)","volume":"17","author":"Glitza","year":"2015","journal-title":"Neuro Oncol"},{"key":"2026052004550431000_11.10.e006947.141","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005923"},{"key":"2026052004550431000_11.10.e006947.142","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005755","article-title":"Efficacy and safety of Lifileucel, a one-time Autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced Melanoma after progression on immune Checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study","volume":"10","author":"Chesney","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026052004550431000_11.10.e006947.143","doi-asserted-by":"crossref","unstructured":"Betof Warner A , Postow MA , Panageas K , et al . A Pilot Trial of Autologous Tumor Infiltrating Lymphocytes (Lifileucel, LN-144) for Patients with Asymptomatic Melanoma Brain Metastases. American Society of Clinical Oncology, 2023.","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS9606"},{"key":"2026052004550431000_11.10.e006947.144","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00097-8"},{"key":"2026052004550431000_11.10.e006947.145","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejca.2017.07.022","article-title":"Final analysis of a randomised trial comparing Pembrolizumab versus investigator-choice chemotherapy for Ipilimumab-refractory advanced Melanoma","volume":"86","author":"Hamid","year":"2017","journal-title":"Eur J Cancer"},{"key":"2026052004550431000_11.10.e006947.146","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000398","article-title":"Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy resistance Taskforce","volume":"8","author":"Kluger","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026052004550431000_11.10.e006947.147","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005920","article-title":"Society for Immunotherapy of cancer (SITC) consensus definitions for resistance to combinations of immune Checkpoint inhibitors with chemotherapy","volume":"11","author":"Rizvi","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026052004550431000_11.10.e006947.148","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005923","article-title":"Society for Immunotherapy of cancer (SITC) consensus definitions for resistance to combinations of immune Checkpoint inhibitors with targeted therapies","volume":"11","author":"Atkins","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026052004550431000_11.10.e006947.149","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ejca.2021.09.023","article-title":"Crossover and rechallenge with Pembrolizumab in recurrent patients from the EORTC 1325-MG\/Keynote-054 phase III trial, Pembrolizumab versus placebo after complete resection of high-risk stage III Melanoma","volume":"158","author":"Eggermont","year":"2021","journal-title":"Eur J Cancer"},{"key":"2026052004550431000_11.10.e006947.150","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.annonc.2020.04.471","article-title":"Management of early Melanoma recurrence despite adjuvant anti-PD-1 antibody therapy","volume":"31","author":"Owen","year":"2020","journal-title":"Ann Oncol"},{"key":"2026052004550431000_11.10.e006947.151","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005755"},{"key":"2026052004550431000_11.10.e006947.152","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2022-CT013","article-title":"Abstract Ct013: S1616: Ipilimumab plus Nivolumab versus Ipilimumab alone in patients with metastatic or Unresectable Melanoma that did not respond to anti-Pd-1 therapy","volume":"82","author":"Vanderwalde","year":"2022","journal-title":"Cancer Res"},{"key":"2026052004550431000_11.10.e006947.153","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2210233"},{"key":"2026052004550431000_11.10.e006947.154","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.3.1039"},{"key":"2026052004550431000_11.10.e006947.155","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0522-3","article-title":"Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic Melanoma and renal cell carcinoma following Pd1 or Pdl1 inhibition","volume":"7","author":"Buchbinder","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2026052004550431000_11.10.e006947.156","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.9520","article-title":"Phase II study of triplet combination Nivolumab (N) with Dabrafenib (D) and Trametinib (T) (Trident) in patients (Pts) with PD-1 Na\u00efve or refractory BRAF-Mutated metastatic Melanoma (MM) with or without active brain metastases","volume":"39","author":"Burton","year":"2021","journal-title":"JCO"},{"key":"2026052004550431000_11.10.e006947.157","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.9504","article-title":"Lenvatinib (Len) plus Pembrolizumab (Pembro) for patients (Pts) with advanced Melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor: updated findings of LEAP-004","volume":"39","author":"Arance","year":"2021","journal-title":"JCO"},{"key":"2026052004550431000_11.10.e006947.158","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2022.08.036","article-title":"Lba3 treatment with tumor-infiltrating lymphocytes (TIL) versus Ipilimumab for advanced Melanoma: results from a multicenter, randomized phase III trial","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"2026052004550431000_11.10.e006947.159","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","article-title":"Tumor-infiltrating lymphocyte therapy or Ipilimumab in advanced Melanoma","volume":"387","author":"Rohaan","year":"2022","journal-title":"N Engl J Med"},{"key":"2026052004550431000_11.10.e006947.160","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.3377"},{"key":"2026052004550431000_11.10.e006947.161","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0623-z"},{"key":"2026052004550431000_11.10.e006947.162","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.08.027"},{"key":"2026052004550431000_11.10.e006947.163","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/jso.23554","article-title":"Intralesional therapy with PV-10 (rose Bengal) for in-transit Melanoma","volume":"109","author":"Ross","year":"2014","journal-title":"J Surg Oncol"},{"key":"2026052004550431000_11.10.e006947.164","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3301885"},{"key":"2026052004550431000_11.10.e006947.165","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.834841","article-title":"Talimogene Laherparepvec: moving from first-in-class to best-in-class","volume":"9","author":"Kaufman","year":"2022","journal-title":"Front Mol Biosci"},{"key":"2026052004550431000_11.10.e006947.166","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0250-5"},{"key":"2026052004550431000_11.10.e006947.167","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0623-z","article-title":"Final analyses of Optim: a randomized phase III trial of Talimogene Laherparepvec versus granulocyte-macrophage colony-stimulating factor in Unresectable stage III\u2013IV Melanoma","volume":"7","author":"Andtbacka","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2026052004550431000_11.10.e006947.168","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic Virotherapy promotes Intratumoral T cell infiltration and improves anti-PD-1 Immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"key":"2026052004550431000_11.10.e006947.169","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-016-0158-5"},{"key":"2026052004550431000_11.10.e006947.170","doi-asserted-by":"crossref","unstructured":"Puzanov I , Chesney J , Collichio F , et al . 433 Talimogene Laherparepvec (T-VEC) in combination with Ipilimumab (IPI) versus IPI alone for advanced Melanoma: 4-year interim analysis of a randomized, open-label, phase 2 trial. 35th anniversary annual meeting (SITC 2020). 35th Anniversary Annual Meeting (SITC 2020); November 2020 doi:10.1136\/jitc-2020-SITC2020.0433","DOI":"10.1136\/jitc-2020-SITC2020.0433"},{"key":"2026052004550431000_11.10.e006947.171","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-016-0116-2","article-title":"Systemic versus local responses in Melanoma patients treated with Talimogene Laherparepvec from a multi-institutional phase II study","volume":"4","author":"Kaufman","year":"2016","journal-title":"J Immunother Cancer"},{"key":"2026052004550431000_11.10.e006947.172","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-017-0250-5","article-title":"Safe and effective administration of T-VEC in a patient with heart transplantation and recurrent locally advanced Melanoma","volume":"5","author":"Schvartsman","year":"2017","journal-title":"J Immunother Cancer"},{"key":"2026052004550431000_11.10.e006947.173","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jdcr.2021.05.005","article-title":"Complete remission from Intralesional Talimogene Laherparepvec for regionally advanced Merkel cell carcinoma in an immunocompromised solid organ transplant patient","volume":"13","author":"Hirotsu","year":"2021","journal-title":"JAAD Case Rep"},{"key":"2026052004550431000_11.10.e006947.174","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-SITC2021.550"},{"key":"2026052004550431000_11.10.e006947.175","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-016-0158-5","article-title":"Into the clinic: talimogene Laherparepvec (T-VEC), a first-in-class Intratumoral Oncolytic viral therapy","volume":"4","author":"Rehman","year":"2016","journal-title":"J Immunother Cancer"},{"key":"2026052004550431000_11.10.e006947.176","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0280"},{"key":"2026052004550431000_11.10.e006947.177","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0425"},{"key":"2026052004550431000_11.10.e006947.178","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2022.08.037","article-title":"LBA39 final 5-year results of the phase II, multicenter, randomized, open-label trial of talimogene laherparepvec (T-VEC) neoadjuvant treatment (tx) plus surgery vs immediate surgery in patients (pts) with resectable stage IIIB-ivm1a melanoma (MEL)","volume":"33","author":"Dummer","year":"2022","journal-title":"Annals of Oncology"},{"key":"2026052004550431000_11.10.e006947.179","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0362-6"},{"key":"2026052004550431000_11.10.e006947.180","article-title":"550 ARTACUS: an open-label, multicenter, phase 1B\/2 study of Rp1 in solid organ transplant recipients with advanced cutaneous malignancies","volume":"9","author":"Luke","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026052004550431000_11.10.e006947.181","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1158\/1078-0432.CCR-19-2217","article-title":"Phase II trial of IL-12 Plasmid Transfection and PD-1 blockade in Immunologically quiescent Melanoma","volume":"26","author":"Algazi","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026052004550431000_11.10.e006947.182","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1158\/2159-8290.CD-18-0280","article-title":"SD-101 in combination with Pembrolizumab in advanced Melanoma: results of a phase IB, multicenter study","volume":"8","author":"Ribas","year":"2018","journal-title":"Cancer Discov"},{"key":"2026052004550431000_11.10.e006947.183","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02229"},{"key":"2026052004550431000_11.10.e006947.184","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1624"},{"key":"2026052004550431000_11.10.e006947.185","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-018-0362-6","article-title":"An update on the society for Immunotherapy of cancer consensus statement on tumor Immunotherapy for the treatment of cutaneous Melanoma: version 2.0","volume":"6","author":"Sullivan","year":"2018","journal-title":"J Immunother Cancer"},{"key":"2026052004550431000_11.10.e006947.186","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002955","article-title":"PET\/CT scan and biopsy-driven approach for safe anti-PD-1 therapy discontinuation in patients with advanced Melanoma","volume":"9","author":"Gibney","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026052004550431000_11.10.e006947.187","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/s41571-020-0399-6","article-title":"Immunotherapy discontinuation - how, and when? data from Melanoma as a paradigm","volume":"17","author":"Robert","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"2026052004550431000_11.10.e006947.188","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1093\/annonc\/mdy330","article-title":"FDG-PET response and outcome from anti-PD-1 therapy in metastatic Melanoma","volume":"29","author":"Tan","year":"2018","journal-title":"Ann Oncol"},{"key":"2026052004550431000_11.10.e006947.189","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00545-3"},{"key":"2026052004550431000_11.10.e006947.190","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2026052004550431000_11.10.e006947.191","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20170457","article-title":"Immune-related tumour response assessment criteria: a comprehensive review","volume":"91","author":"Somarouthu","year":"2018","journal-title":"Br J Radiol"},{"key":"2026052004550431000_11.10.e006947.192","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0198-0"},{"key":"2026052004550431000_11.10.e006947.193","doi-asserted-by":"crossref","DOI":"10.21037\/atm.2018.04.17","article-title":"Which criteria should we use to evaluate the efficacy of immune-Checkpoint inhibitors","volume":"6","author":"Kataoka","year":"2018","journal-title":"Ann Transl Med"},{"key":"2026052004550431000_11.10.e006947.194","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.8501","article-title":"BREAK-MB: A phase II study assessing overall intracranial response rate (OIRR) to Dabrafenib (Gsk2118436) in patients (Pts) with BRAF V600E\/K Mutation-positive Melanoma with brain metastases (Mets)","volume":"30","author":"Kirkwood","year":"2012","journal-title":"JCO"},{"key":"2026052004550431000_11.10.e006947.195","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2379"},{"key":"2026052004550431000_11.10.e006947.196","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1200\/EDBK_200819","article-title":"New era in the management of Melanoma brain metastases","volume":"38","author":"Tawbi","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2026052004550431000_11.10.e006947.197","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz019"},{"key":"2026052004550431000_11.10.e006947.198","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-1545"},{"key":"2026052004550431000_11.10.e006947.199","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-018-0252-y","article-title":"Publisher correction: Neoadjuvant immune Checkpoint blockade in high-risk Resectable Melanoma","volume":"24","author":"Amaria","year":"2018","journal-title":"Nat Med"},{"key":"2026052004550431000_11.10.e006947.200","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41591-019-0357-y","article-title":"A single dose of Neoadjuvant PD-1 blockade predicts clinical outcomes in Resectable Melanoma","volume":"25","author":"Huang","year":"2019","journal-title":"Nat Med"},{"key":"2026052004550431000_11.10.e006947.201","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0114"},{"key":"2026052004550431000_11.10.e006947.202","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.e21569","article-title":"FDG-PET\/CT response and outcome of Neoadjuvant Immunotherapy for clinical stage III Melanoma","volume":"39","author":"De Barros E. Silva","year":"2021","journal-title":"JCO"},{"key":"2026052004550431000_11.10.e006947.203","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30074-8"},{"key":"2026052004550431000_11.10.e006947.204","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0426-7"},{"key":"2026052004550431000_11.10.e006947.205","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26111"},{"key":"2026052004550431000_11.10.e006947.206","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-012-2398-z"},{"key":"2026052004550431000_11.10.e006947.207","doi-asserted-by":"crossref","first-page":"4671","DOI":"10.1158\/1078-0432.CCR-17-0114","article-title":"Immune-related tumor response Dynamics in Melanoma patients treated with Pembrolizumab: identifying markers for clinical outcome and treatment decisions","volume":"23","author":"Nishino","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2026052004550431000_11.10.e006947.208","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9098(199908)71:4<209::AID-JSO1>3.0.CO;2-2"},{"key":"2026052004550431000_11.10.e006947.209","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0672-3"},{"key":"2026052004550431000_11.10.e006947.210","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-018-0426-7","article-title":"Trial reporting in Immuno-oncology (TRIO): an American society of clinical oncology-society for Immunotherapy of cancer statement","volume":"6","author":"Tsimberidou","year":"2018","journal-title":"J Immunother Cancer"},{"key":"2026052004550431000_11.10.e006947.211","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1002\/cncr.26111","article-title":"A phase 2 trial of complete resection for stage IV Melanoma: results of Southwest oncology group clinical trial S9430","volume":"117","author":"Sosman","year":"2011","journal-title":"Cancer"},{"key":"2026052004550431000_11.10.e006947.212","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0282-x"},{"key":"2026052004550431000_11.10.e006947.213","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000413"},{"key":"2026052004550431000_11.10.e006947.214","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz110"},{"key":"2026052004550431000_11.10.e006947.215","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0672-3","article-title":"Patterns of failure after Immunotherapy with Checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic Melanoma","volume":"7","author":"Klemen","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2026052004550431000_11.10.e006947.216","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.1592"},{"key":"2026052004550431000_11.10.e006947.217","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1159\/000505487","article-title":"Systemic antitumor effects and Abscopal responses in Melanoma patients receiving radiation therapy","volume":"98","author":"D\u2019Andrea","year":"2020","journal-title":"Oncology"},{"key":"2026052004550431000_11.10.e006947.218","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-017-0282-x","article-title":"Melanoma brain metastases treated with stereotactic Radiosurgery and concurrent Pembrolizumab display marked regression; efficacy and safety of combined treatment","volume":"5","author":"Anderson","year":"2017","journal-title":"J Immunother Cancer"},{"key":"2026052004550431000_11.10.e006947.219","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000871"},{"key":"2026052004550431000_11.10.e006947.220","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1093\/annonc\/mdz110","article-title":"Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced Melanoma","volume":"30","author":"Jansen","year":"2019","journal-title":"Ann Oncol"},{"key":"2026052004550431000_11.10.e006947.221","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1200\/JCO.2017.75.6270","article-title":"Durable complete response after discontinuation of Pembrolizumab in patients with metastatic Melanoma","volume":"36","author":"Robert","year":"2018","journal-title":"JCO"},{"key":"2026052004550431000_11.10.e006947.222","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0095096"},{"key":"2026052004550431000_11.10.e006947.223","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1634\/theoncologist.2019-0659","article-title":"The safety and efficacy of Checkpoint inhibitors in transplant recipients: A case series and systematic review of literature","volume":"25","author":"Kumar","year":"2020","journal-title":"Oncologist"},{"key":"2026052004550431000_11.10.e006947.224","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/S1470-2045(22)00368-0","article-title":"Immune Checkpoint inhibitors in kidney transplant recipients: a Multicentre, single-arm, phase 1 study","volume":"23","author":"Carroll","year":"2022","journal-title":"Lancet Oncol"},{"key":"2026052004550431000_11.10.e006947.225","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000871","article-title":"Impact of age on the toxicity of immune Checkpoint inhibition","volume":"8","author":"Samani","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026052004550431000_11.10.e006947.226","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.7338"},{"key":"2026052004550431000_11.10.e006947.227","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/cncr.32645","article-title":"Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune Checkpoint inhibitors","volume":"126","author":"Khaki","year":"2020","journal-title":"Cancer"},{"key":"2026052004550431000_11.10.e006947.228","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0095096","article-title":"Risk of Melanoma in people with HIV\/AIDS in the Pre- and post-HAART eras: a systematic review and meta-analysis of cohort studies","volume":"9","author":"Olsen","year":"2014","journal-title":"PLoS One"},{"key":"2026052004550431000_11.10.e006947.229","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08798-7"},{"key":"2026052004550431000_11.10.e006947.230","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1001\/jamaoncol.2018.6737","article-title":"Safety and efficacy of immune Checkpoint inhibitor therapy in patients with HIV infection and advanced-stage cancer: A systematic review","volume":"5","author":"Cook","year":"2019","journal-title":"JAMA Oncol"},{"key":"2026052004550431000_11.10.e006947.231","doi-asserted-by":"crossref","DOI":"10.1177\/15330338211036526","article-title":"Immune Checkpoint inhibitors in special populations","volume":"20","author":"Shan","year":"2021","journal-title":"Technol Cancer Res Treat"},{"key":"2026052004550431000_11.10.e006947.232","doi-asserted-by":"crossref","first-page":"3774","DOI":"10.1200\/JCO.2017.73.7338","article-title":"Modernizing clinical trial eligibility criteria: recommendations of the American society of clinical oncology-friends of cancer research HIV working group","volume":"35","author":"Uldrick","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026052004550431000_11.10.e006947.233","unstructured":"G REaS . NCCN guidelines: cancer in people with HIV (version 1.2022 \u2014 February 3, 2022). National Comprehensive Cancer Network 2022."},{"key":"2026052004550431000_11.10.e006947.234","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/annonc\/mdx696","article-title":"Drastic decrease of the HIV reservoir in a patient treated with Nivolumab for lung cancer","volume":"29","author":"Guihot","year":"2018","journal-title":"Ann Oncol"},{"key":"2026052004550431000_11.10.e006947.235","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-08798-7","article-title":"PD-1 blockade potentiates HIV latency reversal ex vivo in Cd4+ T cells from ART-suppressed individuals","volume":"10","author":"Fromentin","year":"2019","journal-title":"Nat Commun"},{"key":"2026052004550431000_11.10.e006947.236","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2019.102836","article-title":"Treating cancer with Immunotherapy in HIV-positive patients: A challenging reality","volume":"145","author":"Guaitoli","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026052004550431000_11.10.e006947.237","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.03-0538"},{"key":"2026052004550431000_11.10.e006947.238","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/CMR.0000000000000586","article-title":"Pregnancy with successful foetal and maternal outcome in a Melanoma patient treated with Nivolumab in the first trimester: case report and review of the literature","volume":"29","author":"Xu","year":"2019","journal-title":"Melanoma Res"},{"key":"2026052004550431000_11.10.e006947.239","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28282"},{"key":"2026052004550431000_11.10.e006947.240","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100262","article-title":"Immune Checkpoint inhibitor administration during pregnancy: a case series","volume":"6","author":"Andrikopoulou","year":"2021","journal-title":"ESMO Open"},{"key":"2026052004550431000_11.10.e006947.241","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/985646","article-title":"Igg Placental transfer in healthy and pathological pregnancies","volume":"2012","author":"Palmeira","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"2026052004550431000_11.10.e006947.242","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2103485"},{"key":"2026052004550431000_11.10.e006947.243","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1167\/iovs.03-0538","article-title":"Very long-term prognosis of patients with malignant Uveal Melanoma","volume":"44","author":"Kujala","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2026052004550431000_11.10.e006947.244","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz176"},{"key":"2026052004550431000_11.10.e006947.245","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1002\/cncr.28282","article-title":"Clinical activity of Ipilimumab for metastatic Uveal Melanoma: a retrospective review of the Dana-Farber cancer Institute, Massachusetts general hospital, memorial Sloan-Kettering cancer center, and University hospital of Lausanne experience","volume":"119","author":"Luke","year":"2013","journal-title":"Cancer"},{"key":"2026052004550431000_11.10.e006947.246","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0522"},{"key":"2026052004550431000_11.10.e006947.247","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1200\/JCO.20.00605","article-title":"Nivolumab and Ipilimumab in metastatic Uveal Melanoma: results from a single-arm phase II study","volume":"39","author":"Pelster","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026052004550431000_11.10.e006947.248","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0739"},{"key":"2026052004550431000_11.10.e006947.249","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jaad.2018.07.028","article-title":"Identification of patients at risk of metastasis using a Prognostic 31-gene expression profile in subpopulations of Melanoma patients with favorable outcomes by standard criteria","volume":"80","author":"Gastman","year":"2019","journal-title":"Journal of the American Academy of Dermatology"},{"key":"2026052004550431000_11.10.e006947.250","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1093\/annonc\/mdz176","article-title":"Meta-analysis in metastatic Uveal Melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular Melanoma study","volume":"30","author":"Khoja","year":"2019","journal-title":"Ann Oncol"},{"key":"2026052004550431000_11.10.e006947.251","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.9510","article-title":"FOCUS phase 3 trial results: percutaneous hepatic perfusion (PHP) with Melphalan for patients with ocular Melanoma liver metastases (PHP-OCM-301\/301A)","volume":"40","author":"Zager","year":"2022","journal-title":"JCO"},{"key":"2026052004550431000_11.10.e006947.252","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.9258"},{"key":"2026052004550431000_11.10.e006947.253","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-013-3089-0"},{"key":"2026052004550431000_11.10.e006947.254","doi-asserted-by":"publisher","DOI":"10.1016\/j.jss.2020.02.010"},{"key":"2026052004550431000_11.10.e006947.255","unstructured":"Choi Jacob SB . Zhang Hui clinical practices and outcomes of patients with primary Mucosal Melanoma in the adjuvant setting. 2022."},{"key":"2026052004550431000_11.10.e006947.256","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1001150","article-title":"Neoadjuvant Checkpoint inhibitor Immunotherapy for Resectable Mucosal Melanoma","volume":"12","author":"Ho","year":"2022","journal-title":"Front Oncol"},{"key":"2026052004550431000_11.10.e006947.257","doi-asserted-by":"publisher","DOI":"10.1111\/pcmr.12279"},{"key":"2026052004550431000_11.10.e006947.258","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1200\/JCO.2016.67.9258","article-title":"Efficacy and safety of Nivolumab alone or in combination with Ipilimumab in patients with Mucosal Melanoma: A pooled analysis","volume":"35","author":"D\u2019Angelo","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026052004550431000_11.10.e006947.259","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.09.2220","article-title":"1086MO Lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients (pts) with advanced mucosal melanoma after progression on immune checkpoint inhibitors (ICI): Results from the phase II C-144-01 study","volume":"34","author":"Grigoleit","year":"2023","journal-title":"Ann Oncol"},{"key":"2026052004550431000_11.10.e006947.260","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385"},{"key":"2026052004550431000_11.10.e006947.261","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jss.2020.02.010","article-title":"Acral Lentiginous Melanoma: incidence and survival in the United States, 2006-2015, an analysis of the SEER Registry","volume":"251","author":"Huang","year":"2020","journal-title":"J Surg Res"},{"key":"2026052004550431000_11.10.e006947.262","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.11.010"},{"key":"2026052004550431000_11.10.e006947.263","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2012-0483"},{"key":"2026052004550431000_11.10.e006947.264","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/pcmr.12279","article-title":"The mutational burden of Acral Melanoma revealed by whole-genome sequencing and comparative analysis","volume":"27","author":"Furney","year":"2014","journal-title":"Pigment Cell Melanoma Res"},{"key":"2026052004550431000_11.10.e006947.265","doi-asserted-by":"crossref","DOI":"10.1007\/s11864-018-0560-y","article-title":"Diagnosis and management of Acral Lentiginous Melanoma","volume":"19","author":"Nakamura","year":"2018","journal-title":"Curr Treat Options Oncol"},{"key":"2026052004550431000_11.10.e006947.266","first-page":"271","article-title":"Immune Checkpoint inhibitor therapy: key principles when educating patients","volume":"23","author":"Wood","year":"2019","journal-title":"Clin J Oncol Nurs"},{"key":"2026052004550431000_11.10.e006947.267","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune Checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"JCO"},{"key":"2026052004550431000_11.10.e006947.268","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1188\/16.CJON.560-563","article-title":"Oncology nursing and shared decision making for cancer treatment","volume":"20","author":"Tariman","year":"2016","journal-title":"CJON"},{"key":"2026052004550431000_11.10.e006947.269","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000260"},{"key":"2026052004550431000_11.10.e006947.270","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1634\/theoncologist.2012-0483","article-title":"Ipilimumab and its toxicities: A Multidisciplinary approach","volume":"18","author":"Fecher","year":"2013","journal-title":"Oncologist"},{"key":"2026052004550431000_11.10.e006947.271","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ejca.2022.08.004","article-title":"Adjuvant Pembrolizumab versus placebo in Resected high-risk stage II Melanoma: health-related quality of life from the randomized phase 3 KEYNOTE-716 study","volume":"176","author":"Khattak","year":"2022","journal-title":"European Journal of Cancer"},{"key":"2026052004550431000_11.10.e006947.272","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0837"},{"key":"2026052004550431000_11.10.e006947.273","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejca.2017.08.032","article-title":"Patient-reported outcomes in KEYNOTE-006, a randomised study of Pembrolizumab versus Ipilimumab in patients with advanced Melanoma","volume":"86","author":"Petrella","year":"2017","journal-title":"Eur J Cancer"},{"key":"2026052004550431000_11.10.e006947.274","doi-asserted-by":"publisher","DOI":"10.1530\/REP-15-0163"},{"key":"2026052004550431000_11.10.e006947.275","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.e21004","article-title":"Health-related quality of life (Hrqol) in patients with advanced Melanoma receiving Immunotherapies across real-world clinical practice settings","volume":"37","author":"Joseph","year":"2019","journal-title":"JCO"},{"key":"2026052004550431000_11.10.e006947.276","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000260","article-title":"Quality of life in long-term survivors of advanced Melanoma treated with Checkpoint inhibitors","volume":"8","author":"Mamoor","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026052004550431000_11.10.e006947.277","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.9588","article-title":"Financial toxicity and cancer-related distress among Melanoma survivors","volume":"35","author":"Buzaglo","year":"2017","journal-title":"JCO"},{"key":"2026052004550431000_11.10.e006947.278","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1001\/jamadermatol.2019.3353","article-title":"Age-specific incidence of Melanoma in the United States","volume":"156","author":"Paulson","year":"2020","journal-title":"JAMA Dermatol"},{"key":"2026052004550431000_11.10.e006947.279","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0837"},{"key":"2026052004550431000_11.10.e006947.280","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100276","article-title":"Checkpoint inhibitors, fertility, pregnancy, and sexual life: a systematic review","volume":"6","author":"Garutti","year":"2021","journal-title":"ESMO Open"},{"key":"2026052004550431000_11.10.e006947.281","doi-asserted-by":"publisher","DOI":"10.1530\/REP-15-0163"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2023-006947","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T11:55:44Z","timestamp":1779278144000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2023-006947"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":281,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,10,18]]},"published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1136\/jitc-2023-006947"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2023-006947","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10]]}}}